ZNF217: An Oncogenic Transcription Factor and Potential Therapeutic Target for Multiple Human Cancers

被引：2
|
作者：
Wang, Yepeng [1 ]
Ma, Chao [2 ]
Yang, Xuekun [3 ]
Gao, Jun [1 ]
Sun, Zhigang [2 ,4 ]
机构：
[1] Shandong First Med Univ, Cent Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China
[2] Shandong First Med Univ, Cent Hosp, Dept Thorac Surg, Jinan, Shandong, Peoples R China
[3] Shandong First Med Univ, Cent Hosp, Dept Neurol, Jinan, Shandong, Peoples R China
[4] Shandong First Med Univ, Cent Hosp, Dept Thorac Surg, 105 Jiefang Rd, Jinan, Shandong, Peoples R China
来源：
CANCER MANAGEMENT AND RESEARCH | 2024年 / 16卷
关键词：
oncogene; regulation; non-coding RNA; targeted therapy; IN-SITU HYBRIDIZATION; EPITHELIAL-MESENCHYMAL TRANSITION; P15(INK4B) TUMOR-SUPPRESSOR; BREAST-CANCER; POOR-PROGNOSIS; TGF-BETA; TISSUE MICROARRAY; REGULATING ZNF217; DRUG-RESISTANCE; NONCODING RNA;
D O I：
10.2147/CMAR.S431135
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Zinc finger protein 217 (ZNF217) is one of the well-researched members of the Kruppel-like factor transcription factor family. ZNF217 possesses a characteristic structure of zinc finger motifs and plays a crucial role in regulating the biological activities of cells. Recent findings have revealed that ZNF217 is strongly associated with multiple aspects of cancer progression, impacting patient prognosis. Notably, ZNF217 is subject to regulation by non-coding RNAs, suggesting the potential for targeted manipulation of such RNAs as a robust therapeutic avenue for managing cancer in the future. The main purpose of this article is to provide a detailed examination of the role of ZNF217 in human malignant tumors and the regulation of its expression, and to offer new perspectives for cancer treatment.
引用
收藏
页码：49 / 62
页数：14
相关论文
共 50 条
  • [1] The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
    Littlepage, Laurie E.
    Adler, Adam S.
    Kouros-Mehr, Hosein
    Huang, Guiqing
    Chou, Jonathan
    Krig, Sheryl R.
    Griffith, Obi L.
    Korkola, James E.
    Qu, Kun
    Lawson, Devon A.
    Xue, Qing
    Sternlicht, Mark D.
    Dijkgraaf, Gerrit J. P.
    Yaswen, Paul
    Rugo, Hope S.
    Sweeney, Colleen A.
    Collins, Colin C.
    Gray, Joe W.
    Chang, Howard Y.
    Werb, Zena
    CANCER DISCOVERY, 2012, 2 (07) : 638 - 651
  • [2] PAN-CANCER TRANSCRIPTION FACTOR ANALYSES IDENTIFY ZNF217 AS A NOVEL DRIVER IN HGSOC
    Nameki, Robbin
    Fonseca, Marcos A. S.
    Reddy, Jessica
    Vavra, Kevin C.
    Segato, Felipe
    Corona, Rosario I.
    Seo, Ji-Heui
    Liu, Annie
    Abbasi, Forough
    Lin, Xianzhi
    Karlan, Beth Y.
    Freedman, Matthew L.
    Gayther, Simon A.
    Noushmehr, Houtan
    Lawrenson, Kate
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 106 - 106
  • [3] The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells
    Nonet, GH
    Stampfer, MR
    Chin, K
    Gray, JW
    Collins, CC
    Yaswen, P
    CANCER RESEARCH, 2001, 61 (04) : 1250 - 1254
  • [4] Oncogenic protein SALL4 and ZNF217 as prognostic indicators in solid cancers: a meta-analysis of individual studies
    Cheng, Ji
    Gao, Jinbo
    Shuai, Xiaoming
    Tao, Kaixiong
    ONCOTARGET, 2016, 7 (17) : 24314 - 24325
  • [5] Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression
    Li, Peixiang
    Maines-Bandiera, Sarah
    Kuo, Wen-Lin
    Guan, Yinghui
    Sun, Yu
    Hills, Mark
    Huang, Guiqing
    Collins, Collin C.
    Leung, Peter C. K.
    Gray, Joe W.
    Auersperg, Nelly
    INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (09) : 1863 - 1873
  • [6] The transcription factor ZNF217 is an oncogene that promotes an increase in progenitor cells, increases metastasis, and acts via the AKT pathway
    Littlepage, L. E.
    Kouros-Mehr, H.
    Adler, A. S.
    Chou, J.
    Huang, G.
    Collins, C. C.
    Chang, H. Y.
    Gray, J. W.
    Werb, Z.
    MOLECULAR BIOLOGY OF THE CELL, 2011, 22
  • [7] Regulation of expression of the p21CIP1 gene by the transcription factor ZNF217 and MDM2
    Mantsou, Aglaia
    Koutsogiannouli, Evangelia
    Haitoglou, Costas
    Papavassiliou, Athanasios G.
    Papanikolaou, Nikolaos A.
    BIOCHEMISTRY AND CELL BIOLOGY, 2016, 94 (06) : 560 - 568
  • [8] A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers
    Nguyen, Nhan T.
    Vendrell, Julie A.
    Poulard, Coralie
    Gyorffy, Balazs
    Goddard-Leon, Sophie
    Bieche, Ivan
    Corbo, Laura
    Le Romancer, Muriel
    Bachelot, Thomas
    Treilleux, Isabelle
    Cohen, Pascale A.
    MOLECULAR ONCOLOGY, 2014, 8 (08) : 1441 - 1457
  • [9] LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human Cancers
    Xin, Xiaoru
    Li, Qianan
    Fang, Jinyong
    Zhao, Tiejun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers
    Sharma, Tanu
    Zhang, Yuanjin
    Zigrossi, Alexandra
    Cravatt, Benjamin F.
    Kastrati, Irida
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (03) : 561 - 570
12345